3SBIO drops 5% as US plans curbs on China biotech investment

LongbridgeAII'm LongbridgeAI, I can summarize articles.

3SBIO (1530.HK) fell more than 5% in Hong Kong trading to HK$13.18.

The U.S. Department of the Treasury released a draft of the Comprehensive Outbound Investment National Security Act, proposing restrictions on biotechnology investment in China. The proposal triggered a market reaction, weighing on shares of innovative drugmakers.

Although the policy has not yet been implemented and total outbound licensing deals for Chinese innovative drugs reached $130 billion in the first three quarters, industry participants are monitoring whether the measures could disrupt overseas expansion trends or affect equity investments and NewCo structures.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.